SEC For	m 4 FORM			\ CT /				יידוס						<b></b>					
	UNITED STATES SECURITIES AND EXCHANGE COMMIS Washington, D.C. 20549													OMB APPROVAL			VAL 3235-0287		
Section 16. Form 4 or Form 5 obligations may continue. See						A pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										SHIP Estimate hours p			
1. Name and Address of Reporting Person <sup>*</sup> Valantine Hannah						2. Issuer Name <b>and</b> Ticker or Trading Symbol BridgeBio Pharma, Inc. [BBIO]									5. Relationship of Reporting Person(s) to Issue (Check all applicable) X Director 10% Owner				
(Last) (First) (Middle)					<ul> <li>3. Date of Earliest Transaction (Month/Day/Year) 11/15/2023</li> </ul>										Officer (give title Other (speci below) below)				specify
C/O BRIDGEBIO PHARMA, INC. 3160 PORTER DR., SUITE 250					4. 1	Line)										or Joint/Group Filing (Check Applicable m filed by One Reporting Person m filed by More than One Reporting			
(Street) PALO A	LTO C.	A	94304			Dula 10h5 1(a) Transaction Indiantian										Person			
(City)       (State)       (Zip)         Rule 10b5-1(c) Transaction Indication         Image: Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												ed to							
		Tab	le I - Nor	n-Deri	vative	e Se	curit	ies A	cquired	, Di	sposed	of, o	or Ber	eficial	ly Owned	ł			
Date				Date	Date (Month/Day/Year)			2A. Deemed Execution Date, if any (Month/Day/Yea		Code (Instr.		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)			Benefici	es ally Following	Form (D) o	n: Direct r Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
									Code	v	Amoun	t	(A) or (D)	Price	Transac (Instr. 3	tion(s)			(1150.4)
					5/202				M <sup>(1)</sup>		2,91		A	\$8.4		679		D	
Common Stock 11/15											2,91				· · · · ·	1,764		D	
		1	able II -						•		convert			-	Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year		4. Transaction Code (Instr. 8)				6. Date E Expiratio (Month/D	n Dat		) Amou Secu Unde Deriv		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s Illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title		Amount or Number of Shares					
Stock Option (right to	\$8.45	11/15/2023					2,915		(2)		06/22/2032		mmon tock	2,915	\$0.00	102,00	06	D	

## Explanation of Responses:

1. This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on August 16, 2023.

2. 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.

Remarks:

buy)

/s/ Brian C. Stephenson,

Attorney-in-Fact

11/17/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\ast$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.